Multi Million Dollar Funding Package for Acculis Limited Microwave Cancer Treatment

DENMEAD, England--()--Acculis Limited has finalised a multi million dollar funding package to complete commercial development of the needle probe version of its recently launched MTA high power microwave coagulation system. The funding has been secured from private equity sources in the USA.

Where the current MTA product is aimed at the open liver surgery market, our new 1.8mm device will extend large volume microwave coagulation therapy into the lung and bone cancer arenas. said Stuart McIntyre, CEO of Acculis Limited. In the hands of interventional radiologists as well as surgical oncologists this product will allow minimally invasive procedures to be delivered where the precision, speed and power of microwave energy will allow many more treatment options than are possible with existing radiofrequency technology.

Acculis Limited recently announced the first open surgery MTA treatments with a cohort of 14 world-leading cancer centres in the UK, USA and Australia. AUGIS, the UK liver surgeons body, is auditing the clinical use of the system in conjunction with the participating sites.

Using microwave energy to destroy unwanted tissue is much more efficient than previous thermal methods. Microwaves are absorbed within a precise tissue area and the energy deposited wholly in the tissue to be destroyed. This way treatments that previously took hours can now take minutes. This opens up many new treatment opportunities for health professionals in the care of cancer patients. McIntyre explained.

The Acculis System was developed following research at the University of Bath, England in which specialised patented designs allowing efficient deposition of microwave energy tissue were developed. This technology platform has already spawned a product for endometrial ablation and products for venous occlusion and surface tissue coagulation are also in development.

Every year millions of patients present with primary or secondary liver, lung or bone cancers. With new technologies, such as our Acculis MTA system, ablative therapies will be a growing element in the range of treatments available to surgeons and radiologists in addressing these cancers. said McIntyre.

Acculis is a specialist medical device company developing microwave energy ablation systems for oncology applications. Acculis is part of the Microsulis group of companies. Microsulis and Acculis are based in Hampshire, England.

Contacts

Acculis
Caroline Hall, +44 2392 240011
www.acculis.com

Contacts

Acculis
Caroline Hall, +44 2392 240011
www.acculis.com